济民药业,关爱无限 www.pidrug.com
香港济民药业微信二维码
198 9654 1773
当前位置:首页 > 药品资讯 > 精神科 > Viibryd(维拉佐酮[vilazodone))

Viibryd(维拉佐酮[vilazodone))

[ 人气:135 | 日期: 2020-08-04 | 返回 | 打印 ]
Viibryd(维拉佐酮[vilazodone))
药品名称:Viibryd(维拉佐酮[vilazodone))
药品别名:维拉佐酮
英 文 名:vilazodone
药品价格:$ 美国市场售价 290.53 美元
研发公司:
适 用 症:适用于治疗重度抑郁症(MDD)。
型号规格:片剂,每片含有效成份10mg(day1--7),20mg(day8--30),每盒2套装。
药品详情:

【适应症】
 
    本品适用于治疗重度抑郁症(MDD)。

Viibryd(维拉佐酮[vilazodone))_香港济民药业
 
【规格】
  本品为片剂,每片含有效成份10mg(day1--7),20mg(day8--30),每盒2套装。
 
【服用方法】
  推荐的剂量为每天1次,每次40mg。
 
【注意事项】
(1)临床恶化/自杀风险:监视患者临床恶化和自杀想法或行为。
(2)5-羟色胺综合征或神经阻滞剂恶性综合征[神经阻滞剂恶性综合征]:用治疗可能发生。终止和开始支持治疗。
(3)癫痫发作:用治疗可能发生。有癫痫病患者中慎用。
(4)异常出血:治疗可能增加出血的风险。伴随非甾体抗炎药(NSAIDs),阿司匹林,或影响凝血的其它药物时慎用。
(5)躁狂的激活/轻度躁狂:用治疗可能发生。筛选双相障碍(躁郁症)患者。
(6)用Viibryd治疗的终止:建议逐渐减低剂量而不是突然停止。
(7)低钠血症:伴随不适当抗利尿即使分泌综合征(SIADH)可能发生。
 
【不良反应】
  最常见不良反应(发生率≥5%和至少安慰剂率两倍)是:腹泻,恶心,呕吐,和失眠。

 
Viibryd(Vilazodone)

 
Vilazodone, sold under the brand name Viibryd among others, is a medication used to treat major depressive disorder.[1] While it was being studied for generalized anxiety disorder such research had stopped as of 2017.[3] It is taken by mouth.[1]
 
Common side effects include nausea, diarrhea, and trouble sleeping.[1] Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and SIADH.[1] A withdrawal syndrome may occur if the dose is rapidly decreased.[1] Use during pregnancy and breastfeeding is not generally recommended.[4] It is in the serotonin modulator class of medications and is believed to work both as an SSRI and activator of the 5-HT1A receptor.[1]
 
Vilazodone was approved for medical use in the United States in 2011.[1] It is not approved in other countries as of 2016.[5] In the United States the wholesale cost for a month of medication is about 261 USD.[6] In 2016 it was the 278th most prescribed medication in the United States with more than a million prescriptions.[7]
 
Medical uses
 
According to two eight-week trials in adults, vilazodone has an antidepressant response after one week of treatment. After eight weeks it resulted in a 13% greater response than placebo. Remission rates, however, were not significantly different versus placebo.[8]
 
According to FDA staff, "it is unknown whether [vilazodone] has any advantages compared to other drugs in the antidepressant class."[9]
 
Development for generalized anxiety disorder has been stopped as of 2017.[3]
  
Adverse effects
 
On September 6, 2016, the FDA wrote a letter to Forest Labs about Viibryd. New warnings will be added to the Viibryd label related to a link between the drug and acute pancreatitis.[10] Acute pancreatitis can lead to serious injury and even death. Pancreatitis, especially if it reoccurs, can lead to pancreatic cancer, which is almost always fatal.
 
Additionally, it is expected that new warnings related to sleep paralysis will also be added to the Viibryd label and prescribing information. Sleep paralysis is a condition in which a person is awake but cannot move or speak. Generally, sleep paralysis occurs upon waking and lasts less than one minute. Although sleep paralysis is a serious condition, and can cause psychological harm in the most severe cases, the condition is generally not life threatening.
 
After a one-year, open-label study assessing the safety and tolerability of vilazodone in people with major depressive disorder, the most common adverse effects were diarrhea(35.7%), nausea (31.6%), and headache (20.0%); greater than 90% of these adverse effects were mild or moderate.[8] Whereas in randomized controlled trials these rates were 28%, 23.4% and 13.3%, respectively.[8] In contrast to other SSRIs, initial trials showed that vilazodone did not cause decreased sexual desire/function, which often cause people to abandon their use.[11] Incidence of adverse effects include:[2]
 
Very common adverse effects (incidence >10%)
 
§  Nausea
§  Diarrhea
§  Headache
 
Common adverse effects (1–10% incidence)
 
§  Vomiting
§  Dry mouth
§  Dizziness
§  Insomnia
 
Uncommon adverse effects (0.1–1% incidence)
 
§  Somnolence
§  Paraesthesia
§  Tremor
§  Abnormal dreams
§  Libido decreased
§  Restlessness
§  Akathisia
§  Restless legs syndrome
§  Abnormal orgasms (male persons only)
§  Delayed ejaculations (male persons only)
§  Erectile dysfunction (male persons only)
§  Fatigue
§  Feeling jittery
§  Palpitations
§  Ventricular premature contractions
§  Arthralgia
§  Increased appetite
 
Rare adverse effects (<0.1% incidence)
 
§  Serotonin syndrome—a serious adverse effect characterised by:
·         Nausea
·         Vomiting
·         Mental status change (e.g. confusion, hallucinations, agitation, coma, stupor)
·         Muscle rigidity
·         Tremor
·         Myoclonus
·         Hyperreflexia—overresponsive/overactive reflexes
·         Hyperthermia—elevated body temperature
·         Autonomic instability (e.g. tachycardia, dizziness, abnormally excessive sweating, etc.)
§  Mania/hypomania—a potentially dangerously elated/agitated mood. Every antidepressant has the potential to induce these psychiatric reactions. They are particularly problematic in those with a history of hypomania/mania such as those with bipolar disorder.[12]
 
Unknown-incidence adverse effects
 
§  Suicidal ideation—all antidepressants can cause suicidal ideation especially in young adults and adolescents under the age of 25.
§  Abnormal bleeding—the SSRIs are known for their ability to increase the incidence of gastrointestinal bleeds and other bleeding abnormalities.[12][13][14]
§  Seizures
§  Syndrome of inappropriate antidiuretic hormone secretion (SIADH)—a condition characterised by an abnormally excessive secretion of antidiuretic hormone causing potentially-fatal electrolyte abnormalities (such as hyponatraemia).
§  Hyponatraemia (a complication of the former)—low blood sodium.
 
 




注:药品如有新包装,以新包装为准。以上资讯仅供医护人员内部讨论,不作任何用药依据,具体用药指引,请咨询主治医师。

更多相关资讯:返回顶部
最新药品资讯
  • Venclyxto(维奈妥拉)联合MabThera治疗慢淋白血病,患者死亡风险降低!
  • Tagrisso(Osimertinib)在英国获批用于两种肺癌适应症的治疗
  • ziritaxestat治疗弥漫性皮肤系统性硬化症(dcSSc)2期概念验证研究成功!
  • 美国FDA批准GSK三联疗法:可同时治疗哮喘和慢阻肺
  • NBIb-1817一次性治疗帕金森病(PD)显著改善运动功能、延长ON时间
  • 口服抗生素tebipenem HBr治疗cUTI和AP关键III期临床成功,疗效不劣于ertapenem
  • 下一代选择性免疫调节剂IMU-838治疗多发性硬化症(RRMS)具有显著疗效,有良好的安全性和耐受性!
  • Fintepla(芬氟拉明)口服溶液治疗Dravet综合征相关癫痫的第三项3期研究结果:抽搐发作显著减少
  • 视神经脊髓炎谱系障碍(NMOSD)创新药Enspryng(satralizumab)获美FDA批准
  • Fasenra与标准类固醇同时治疗鼻息肉三期临床结果积极
  • Darzalex Faspro申请新适应症,治疗轻链(AL)淀粉样变性!
  • 地诺单抗(Xgeva,denosumab)治疗实体瘤骨转移疗效怎样?
  • 新药IDH1抑制剂Tibsovo治疗胆管癌效果怎么样?
  • 拜耳Nubeqa(达罗他胺)治疗非转移性去势抵抗性前列腺癌显著延长患者生存!
  • FDA对罗氏Tecentriq治疗三阴性乳腺癌研究发出警告!
  • 加码多发性硬化症!罗氏启动三项临床试验研究
  • Xeglyze说明书-价格-功效与作用-副作用
  • 赛诺菲/再生元Dupixent(达必妥®)显著延缓哮喘患者肺功能下降:疗效维持3年!
  • 默沙东止咳药gefapixant2项关键III期临床试验成功:咳嗽频率显著降低
  • Ryplazim(纤溶酶原)再次申请上市:首个先天性纤溶酶原缺乏症(C-PLGD)治疗药物!
  • 拜耳Adempas用于经PDE5i治疗反应不足的肺动脉高压(PAH)患者IV期临床成功
  • Midostaurin(米哚妥林)适应症是什么?优势在哪里?
  • 艾普利Apixaban可以在哪里买到正品?
  • 维奈妥拉/维奈托克(VENETOCLAX)怎么服用?注意事项是什么?
  • 芦可替尼Ruxolitinib治疗特应性皮炎效果好不好?
  • 巯嘌呤片(6-MP)Puri-nethol治疗急性白血病效果如何?
  • 晚期HCC患者能从Ramucirumab中获益吗?
  • 赫赛汀+拉帕替尼治疗乳腺癌效果更好
  • 欧盟批准Imfinzi(英飞凡):一线治疗广泛期小细胞肺癌(ES-SCLC)!
  • 第三代强效COMT抑制剂Ongentys(opicapone)用于治疗帕金森病(PD)的新药在日本上市!


  • 如您发现本网站有文字编辑或内容错误,请点击此处发送(需要安装有foxmail或outlook支持),


    或发邮件至:info@morecare.hk,香港济民药业感谢您的到访!


    欢迎您添加香港济民药业微信,或在公众号内留言。

    香港济民微信公众号
    • 香港济民药业友情链接
    • 友情链接

    联系我们:

    地址:
    Rm. 314, Sun Ling Plaza, 30 On Kui Street, Fanling, HONG KONG
    邮箱:
    info@pidrug.com
    电话:
    198 9654 1773
    粤ICP备17150936号
    香港济民药业官方网站
    • 关注我们 :
    • 香港济民药业微博
    • 关注香港济民药业博客
    • 香港济民药业微信公众号